Cutaneous basal cell carcinoma · 5 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Vismodegib monotherapy Variant #01 | — | R 87 723 | 540d | — | — | ~2 | ~R 175 447 indirect | — |
Cisplatin and Doxorubicin Variant #01 | — | R 1 434 | 21d | ~5.7 mo | ~12.3 mo | ~3 | ~R 4 301 PFS proxy · indirect | 4 |
Cisplatin and Paclitaxel (TP) Variant #02 | — | R 1 315 | 21d | ~6.9 mo | ~12.9 mo | ~7 | ~R 9 204 PFS proxy · indirect | 22 |
Sonidegib monotherapy Variant #01 Partial | — | — | 28d | — | — | ~2 | — | — |
Cemiplimab monotherapy Variant #01 Partial | — | — | 21d | ~10.3 mo | ~19.1 mo | ~48 | — | 7 |
5 of 5 regimens shown